Indivior Pharmaceuticals financials
$36.59−0.79%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $343.0M | $317.0M | $358.0M | $314.0M | $302.0M | $266.0M | $299.0M | $307.0M | $299.0M | $284.0M | — |
| Gross profit | $293.0M | $277.0M | $291.0M | $231.0M | $250.0M | $222.0M | $251.0M | $241.0M | $220.0M | $246.0M | — |
| Gross margin | 85.4% | 87.4% | 81.3% | 73.6% | 82.8% | 83.5% | 83.9% | 78.5% | 73.6% | 86.6% | — |
| Operating income | $159.0M | $137.0M | $81.0M | $43.0M | $71.0M | $67.0M | $46.0M | $36.0M | -$118.0M | $75.0M | — |
| Net income | $122.0M | $89.0M | $102.0M | $42.0M | $18.0M | $47.0M | $21.0M | $22.0M | -$97.0M | $61.0M | — |
| Net margin | 35.6% | 28.1% | 28.5% | 13.4% | 6.0% | 17.7% | 7.0% | 7.2% | −32.4% | 21.5% | — |
| Diluted EPS | $0.98 | $0.69 | $0.77 | $0.33 | $0.14 | $0.38 | $0.17 | $0.16 | $-0.72 | $0.45 | — |
| EBITDA | $161.0M | $139.0M | $85.0M | $46.0M | $73.0M | $70.0M | $50.0M | $77.0M | $44.0M | $80.0M | $0.00 |
| Operating cash flow | $230.0M | -$10.0M | -$221.0M | -$39.0M | $160.0M | $73.0M | -$17.0M | $2.0M | $88.0M | -$37.0M | — |
| Free cash flow | $223.0M | -$30.0M | -$245.0M | -$59.0M | $143.0M | $68.0M | -$33.0M | -$5.0M | $84.0M | -$39.0M | — |
| Diluted shares | 124.0M | 129.0M | 132.0M | 129.0M | 126.0M | 125.0M | 127.0M | 133.0M | 135.0M | 137.0M | 137.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $222.0M | $175.0M | $195.0M | $445.0M | $510.0M | $372.0M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.0M |
| Total debt | $487.0M | $486.0M | $319.0M | $322.0M | $326.0M | $329.0M |
| Total assets | $1.23B | $1.20B | $1.20B | $1.42B | $1.45B | $1.38B |
| Total liabilities | $1.44B | $1.34B | $1.30B | $1.62B | $1.71B | $1.66B |
| Shareholders' equity | -$208.0M | -$144.0M | -$99.0M | -$207.0M | -$257.0M | -$286.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology